GlaxoSmithKline's ACS Phase III Punt Fails To Pay Off
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's novel anti-inflammatory losmapimod has failed to reduce major cardiac adverse events in heart attack patients in a Phase III study that some have said was a bit of a bet.